Kite Pharma

Kite Pharma

Kite Pharma was founded in 2009 and acquired by Gilead Sciences in 2017, a transaction that valued the then-pre-revenue company at roughly $11.9 billion. The acquisition was a bet that autologous cell therapy — extracting, re-engineering, and reinfusing a patient's immune cells — could become a commercial reality. Gilead chose to maintain the Kite brand and keep its research-and-manufacturing engine largely intact rather than absorb it into the parent's existing oncology division, preserving what was at the time a distinct culture of rapid-cycle development. Kite's platform centers on chimeric antigen receptor (CAR) T-cell therapies, with Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) as its two commercially approved products in multiple hematologic malignancies. The firm's pipeline stretches into novel targets and modalities, including allogeneic cell therapies and next-generation manufacturing processes aimed at reducing the vein-to-vein time. In early 2026, Gilead moved to acquire Arcellx to secure anito-cel, a late-stage BCMA-directed CAR T for multiple myeloma, signaling an intent to expand the Kite portfolio deeper into solid-tumor-adjacent indications. The manufacturing network — a structural cost differentiator few cell-therapy developers replicate — includes facilities in El Segundo, California; Frederick, Maryland; and Amsterdam, Netherlands. As a wholly owned subsidiary, Kite does not disclose standalone financials or employee counts. Gilead's annual filings consolidate Kite's results within its oncology segment, which reported $2.2 billion in revenue for full-year 2025. In February 2026, the FDA approved a label update for Yescarta covering relapsed/refractory primary central nervous system lymphoma, expanding its addressable patient population. Later that spring, new clinical data presented at ASCO and EHA 2026 highlighted momentum across both cell therapy and antibody-drug conjugate programs, further embedding Kite within Gilead's broader oncology strategy. Kite's structural distinction lies in operating as a dedicated cell-therapy unit inside a major pharmaceutical company — a configuration that gives it priority access to a parent's commercial infrastructure and capital reserves while still competing against standalone biotechs on pace of innovation. Gilead's willingness to make bolt-on acquisitions like Arcellx on Kite's behalf demonstrates that the subsidiary operates as a platform, not merely a product line. The unanswered question for allocators — publicly unknowable — is whether Kite's governance independence will persist as Gilead's oncology ambitions increasingly sit at the center of the parent's post-virology growth thesis.